<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640846</url>
  </required_header>
  <id_info>
    <org_study_id>K050711</org_study_id>
    <nct_id>NCT02640846</nct_id>
  </id_info>
  <brief_title>Effects of Levosimendan and Milrinone on Left and Right Ventricular Function in Septic Cardiomyopathy</brief_title>
  <acronym>SCLM</acronym>
  <official_title>Potential Differences Between Levosimendan and Milrinone on Hemodynamic Variables in Patients With Septic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effects of milrinone(Corotrope) and
      levosimendan(Simdax) on septic cardiomyopathy using pulmonary artery catheter, conventional
      and strain echocardiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized study where 30 patients with septic shock and myocardial
      dysfunction in echocardiogram, during the care in ICU, will be included. Patients with a
      history of previous heart disease will be excluded from the study. Each patient will be
      randomized and blinded to receive either milrinone or levosimendan. Before giving one of
      these inotropic agents, hemodynamic variables as blood pressure, cardiac output, pulmonary
      artery occlusion pressure (PAOP) will be continuously monitored with ECG, arterial line and
      pulmonary artery catheter (PAC). Two doses of respective inotropic drug will be administered
      according to drug recommendations. A) milrinone bolus injection 50 mcg/kg followed by
      infusion 0,4 mcg/kg/min and 0,8 mcg/kg/min. B) levosimendan bolus injection 12 mg/kg followed
      by infusion 0,1 mcg/kg/min and 0,2 mcg/kg/min.

      After 30 minutes of treatment with respective drug and dosage, the cardiac function will be
      assessed with echocardiography and systemic hemodynamics. Echocardiograms will be analysed
      for the determination of LV an RV strain. Potential differences between the two agents on
      hemodynamic and respiratory variables, as well as echo and strain measurements will be
      analysed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in LV systolic strain</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Changes in LV systolic function (global strain) will be assessed by 2D speckle tracking echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in RV systolic strain</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Changes in RV systolic function (RV free wall strain) will be assessed by 2D speckle tracking echocardiography</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Septic Shock</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milrinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doser</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.</description>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Simdax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.</description>
    <arm_group_label>Milrinone</arm_group_label>
    <other_name>Corotrope</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic shock.

          -  All patients will be resuscitated with fluids before the inclusion.

          -  Need of Norepinephrine infusion.

          -  Myocardial dysfunction in echocardiogram, either LVEF &lt; 50% or Global Left Ventricular
             Systolic strain over -15%.

        Exclusion Criteria:

          -  History of previous heart disease or pulmonary hypertension.

          -  Age &lt; 18 years.

          -  Cardiac arrhythmia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Sahlgrenska Academy, dep of clinical science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keti Dalla, MD</last_name>
    <phone>+46708876854</phone>
    <email>keti.dalla@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <phone>+46703682898</phone>
    <email>sven-erik.ricksten@aniv.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central intensivvårdsavdelning Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keti Dalla, MD</last_name>
      <phone>46708876854</phone>
      <email>keti.dalla@vgregion.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Keti Dalla</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Levosimendan</keyword>
  <keyword>Milrinone</keyword>
  <keyword>Myocardial strain</keyword>
  <keyword>Septic cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

